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Abstract 
 
Proliposome powders were prepared via a slurry method using sorbitol or D-mannitol as carbohydrate 
carriers in 1:10 or 1:15 w/w lipid phase to carrier ratios. Soya phosphatidylcholine (SPC) and 
cholesterol were employed as a lipid phase and Beclometasone dipropionate (BDP) was incorporated 
as a model drug. Direct compaction using a Minipress was applied on the lipid-enriched powder in 
order to manufacture proliposome tablets. Sorbitol-based proliposome tablets in a 1:15 w/w ratio were 
found to be the best formulation as it exhibited excellent powder flowability with an angle of repose of 
25.62 ± 1.08°, and when compacted the resultant tablets had low friability (0.20 ± 0.03%), appropriate 
hardness (crushing strength) (120.67 ± 12.04 N), short disintegration time (5.85 ± 0.66 min), and 
appropriate weight uniformity. Moreover, upon hydration into liposomes, the entrapment efficiency for 
sorbitol formulations in both 1:10 and 1:15 lipid to carrier ratios were significantly higher (53.82 ± 
6.42% and 57.43 ± 9.12%) than D-mannitol formulations (39.90 ± 4.30% and 35.22 ± 6.50%), 
respectively. Extended stability testing was conducted for 18 months, at three different temperature 
conditions (Fridge Temperature (FT; 6°C), Room Temperature (RT; 22°C) and High Temperature 
(HT; 40°C)) for sorbitol-based proliposome tablets (1:15 w/w ratio). Volume median diameter (VMD) 
and zeta potential significantly changed from 5.90 ± 0.70 µm to 14.79 ± 0.79 µm and from -3.08 ± 
0.26 mV to -11.97 ± 0.26 mV respectively at month 18, when samples were stored under HT 
conditions. Moreover, the entrapment efficiency of BDP decreased from 57.43 ± 9.12% to 17.93 ± 
5.37% following 18 months storage under HT conditions. Overall, in this study for the first time, 
proliposome tablets were manufactured and thoroughly characterized, and sorbitol showed to be a 
promising carrier.  
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1. INTRODUCTION 
Liposomes are commonly used as carriers for many pharmaceutically active compounds; these, if 
hydrophobic, are entrapped into the liposome bilayers, or, if hydrophilic, into the central aqueous core 
of the liposome. Although liposomes are established drug carriers, they exhibit instability during 
storage (Hunt and Tsang, 1981, Khan et al., 2013, Khan et al., 2016), resulting in drug leakage, as 
well as aggregation and fusion of the liposome vesicles (Wong and Thompson, 1982). In order to 
overcome these issues, liposomes have been generated from stable dry formulations known as 
proliposomes (Payne et al., 1986b, Payne et al., 1986a, Khan et al., 2015). Proliposomes are 
comprised of a lipid component (e.g. phospholipid, cholesterol and drug), which forms a thin film 
coated onto carbohydrates carrier particles (Payne et al., 1986b). These proliposomes are then 
hydrated to form liposomes via addition of an aqueous solvent.  
Many formulations are available in powder form due to their mechanical feasibility and stability. 
However, powder formulations are typically challenging to manage in terms of large scale 
manufacture, owing to their bulkiness; in addition to health and environmental risks associated with 
ultrafine solids that might be present in the powder (EPA, 2013). For the aforementioned reasons, 
powders are commonly tableted, offering a plethora of benefits, including simplicity and economic 
feasibility of preparation, stability and convenience in handling, packaging and dispensing (Saker and 
Alanazi, 2013).  
The strength exhibited by tablets is heavily dependent upon preparation technique  and importantly, 
the composition of the powder (Sinka et al., 2009). In addition to the active pharmaceutical ingredient 
(API), diluent excipients used in powder and tablet manufacture are typically safe additives such as 
carbohydrates. Furthermore, small concentrations of functional additives such as disintegrants and 
glidants are incorporated (Rojas et al., 2014). Tablets are considered economical to manufacture 
(Sastry et al., 2000, Jivraj et al., 2000), being one of the most widely available formulations in the 
pharmaceutical industry. A key advantage associated with preparing medicines in the form of tablets 
is the preserved stability of the drug. Many tablets are inherently stable due to the omission of certain 
ingredients, or presence of certain thermo or moisture stable excipients.  
This work aims to develop and assess proliposome powders that can be compressed into tablets 
using a slurry-based approach we published recently to manufacture the proliposomes (Khan et al., 
2015, Khan et al., 2017). Two individual proliposome formulations, with varying carbohydrate carrier 
(sorbitol or D-Mannitol) and lipid to carrier ratio (i.e. 1:10 and 1:15 w/w) were investigated, and the 
influence of proliposome powder flowability on compressibility into tablets was explored. Furthermore, 
the resultant tablets were characterized and checked against standard quality control (QC) tests 
including weight uniformity, disintegration time, Hardness testing (i.e. crushing strength) and friability 
testing in concordance to BP and USP standards. Moreover, entrapment studies were conducted to 
evaluate the potential of the proliposome tablets at providing controlled release of the model 
  
antiasthma drug Beclomethasone dipropionate (BDP). Formulations were stored for 18 months using 
three different temperatures, and subsequently QC tests were performed; and following hydration with 
aqueous phase to generate liposomes, size and zeta potential were analysed to evaluate formulation 
stability. This is the first study that employed the slurry-based proliposome method to generate tablets 
with extended stability studies of 18 months. 
 
2. MATERIALS AND METHODS 
2.1. Materials 
Sorbitol (250 - 700 µm; water solubility = 2350 mg/ml), ferric chloride and ammonium thiocyanate 
were purchased from VWR (BDH Prolab), UK. D-mannitol (≥98%; <250 µm; water solubility = 100 
mg/ml), Beclometasone dipropionate (BDP, ≥99%), cholesterol (≥99%) and Deuterium oxide (D2O, 
1.105 g/ml density and 99.8% purity) were purchased from Sigma-Aldrich, UK. Soya 
phosphatidylcholine (SPC; Lipoid S-100; 94% purity) was a gift from Lipoid, Steinhausen, Switzerland. 
HPLC-grades of methanol and water were supplied by Fischer Scientific Ltd, UK, and absolute 
ethanol and chloroform (AnalaR grade) were purchased from Fischer Scientific Ltd., UK.  
 
2.2. Manufacture of proliposomes powder using the "Slurry" method 
Proliposomes were manufactured in using the "Slurry" method (Khan et al., 2015, Khan et al., 2017). 
Sorbitol or D-mannitol were chosen as carbohydrate carriers. SPC and cholesterol were incorporated 
in a 1:1 mole ratio as a lipid phase (250 mg), and BDP was included at 2 mole% of the lipid phase. 
Two different formulation ratios were prepared for each carrier; 1:10 and 1:15 w/w lipid to carrier. In 
the preparation of 1:10 w/w lipid to carrier ratio proliposome formulation, 2.50 g of carbohydrate 
carrier was added in a pear-shaped flask (100 ml). Lipid phase was prepared by dissolving the lipid 
constituents in ethanol, so that the overall concentration of solid constituents dispersed or dissolved in 
ethanol was 333 mg/ml. The resultant alcoholic solution with or without BDP was then poured onto 
the carbohydrate carrier in the round-bottom flask. Similarly, for the 1:15 w/w formulation ratios, 3.75 
g of carbohydrate was used, and the remaining excipients were kept constant. The pear-shaped flask 
was then attached to a rotary evaporator (Buchi Rotavapor R-114, Buchi, Switzerland), partially 
immersed in a water bath that was previously adjusted to 45°C (Buchi Waterbathe B-480, Buchi, 
Switzerland). A vacuum pump (Buchi Vac V-501) was used to evaporate the ethanol with a maximum 
rotation speed of 280 rpm for 2 h. Subsequently, the generated negative pressure was released and 
the flask was detached from the rotary evaporator. The yielded dry powder (i.e. proliposomes) was 
collected and stored in an air-tight container at -18°C for subsequent studies. 
 
2.3. Lipid quantification via the Stewart assay 
  
Lipid quantification was performed using the Stewart assay (Stewart, 1980). Liposome samples (1 ml) 
were individually hydrated from sorbitol or D-mannitol-based proliposomes, each sample was placed 
in a centrifuge tube and ethanol was added to convert the liposome suspension into an ethanolic lipid 
solution. The samples were placed at 90°C in an oven overnight to evaporate the ethanol and obtain 
a lipid deposit. Chloroform (2 ml) and ammonium ferrothiocyanate solution (2 ml) (prepared by 
dissolving 7.60 g of ammonium thiocyanate and 6.76 g of ferric chloride in deionised water up to 250 
ml) was poured into the centrifuge tube. Vortex-mixing (Fision WhirliMixer, Fision scientific equipment, 
Leicestershire, UK) was conducted for 1 min, followed by 5 min of centrifugation with a speed of 300 g 
at 4°C via a bench centrifuge (Jouan B4i, Thermo Electron Corporation, UK). The chloroform layer 
containing the lipid was separated and quantified via UV-Visible Spectrophotometer at 488 nm 
(Jenway, 7315, Bibby Scientific Ltd, UK) against a calibration curve constructed using lipid dissolved 
in chloroform (40 - 80 µg/ml). 
 
2.4. Compressibility index and Hausner ratio determination via tapped density studies 
A graduated cylinder with 1 ml increments and a volume of 50 ml was implemented to test the 
powdered sample (USP., 2015b, BP., 2016d). A set amount of 15 g (either coarse carrier or 
proliposome powder) was transferred into the cylinder, after which the graduated cylinder was tapped 
manually on a hard surface for 2 - 3 repetitions in order to level the formulation. Then, the initial or 
unsettled apparent volume (Vo) of the powder was noted. The cylinder was then affixed to a tapped 
density tester (Agilent technologies, USA) for automated controlled tapping. The apparatus was set at 
a rate of 1500 ± 15 taps for 5 min (i.e. 300 ± 15 taps per min) and the height from which the cylinder 
was tapped (14 ± 2 mm) was fixed. Post tapping, the final tapped volume (Vf) was recorded. Both 
compressibility index (Equation 1) and Hausner ratio (Equation 2) were calculated from values 
generated from the tapped density experiments (i.e. Vo and Vf).  
Carr’s scale exhibits (Table 1) the degree or quality of powder flow in correspondence to values given 
in compressibility index and hausner ratio, which indicate powder characteristics (Carr, 1965). 
Equation 1:   	
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2.5. Angle of repose (AOR) 
Coarse carbohydrate or proliposome powder (15 g) were put forward for testing. Powder was allowed 
to pass through a funnel at a set height (2 - 4 cm), allowing for the formation of a cone. During cone 
formation, the funnel was elevated between the set height range (2 - 4 cm) in order to maintain a 
  
constant distance from the powder cone as it formed (BP., 2016c). Any improper or asymmetrical 
cone formation was discarded and the measurement repeated until uniform cone formation was 
achieved. A level and smooth surface was ensured for this process. Upon successful cone formation, 
the angle formed through the formation process was established using a protractor, which was kept 
parallel to the base of the cone to measure the AOR (Wong, 2002). Generated values were used to 
classify the powders in accordance to Carr’s scale. 
 
2.6. Direct compression of proliposome powder 
Proliposome powders were employed to manufacture novel proliposome tablets using a Riva 
Minipress MII SA single punch machine (Cenova 4018 Ciudadela, Buenos Aires, Argentina). Tablets 
were prepared using the provided punches (6 mm in diameter). Tablets were typically weighed 
between an average of 90.17 ± 4.30 - 91.97 ± 2.81 mg for sorbitol-based proliposome and 91.44 ± 
4.21 - 92.16 ± 3.60 mg for D-mannitol-based proliposome tablets (1:10 and 1:15 w/w lipid to carrier 
ratios, with and without BDP). Proliposome tablets (from sorbitol-based proliposome powder with 1:15 
w/w lipid to carrier ratio) manufactured through single punch machine via automated route were 
manufactured at a rate of 20 ± 4 tablets per min, and with a compressive force ranging between 3.00 
and 4.50 kN. Manufacturing conditions were the same for all formulations tested.  
 
2.7. Uniformity of weight (Weight variation) 
Ten tablets were selected randomly from each batch; each tablet was weighed individually using a 
calibrated balance (PI-225DA Denver Instruments, Germany). The mean weight of these tablets was 
then ascertained using equation 3, and the variance of each tablet from the mean weight was 
calculated (BP., 2016e). 
Equation 3:   456	7
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‘X’ is weight of individual tablet 
 
2.8. Disintegration testing 
An Erweka disintegration tester (GmbH, type TBH 220D, D-63150 Heusenstamm, Germany) was 
used to study the disintegration time of tablets. The rack assembly was placed in 1,000 ml glass 
beaker filled with deionized water up to the level (800 - 900 ml), where it was covering a distance of 
55 ±2 mm in the beaker. Thermostatic arrangement was ensured by maintaining the temperature at 
37°C. Six proliposome tablets were placed in six tubes individually, followed by positioning of the six 
small plastic disks over the tablets (USP., 2015a, BP., 2016a). Disintegration time was noted for 
tablets tested, in triplicate. 
  
 
2.9. Tablets hardness (crushing strength) 
A specialised Erweka hardness tester (GmbH, type TBH 220D, D-63150 Heusenstamm, Germany) 
was employed to measure the mechanical integrity (breaking force) of the proliposome tablets. Prior 
to assessment of tablet hardness, the machine was calibrated with no tablets, followed by 
assessment of the crushing strength (measured in Newton) of ten randomly selected proliposome 
tablets. 
 
2.10. Friability testing 
Proliposome tablets (6.5 g) were selected randomly; cleaned, weighed and placed into the plastic 
drum of the Erweka friability tester (GmbH, Type TA 120, D-63150, Heusenstamm, Germany). Upon 
testing, the drum was attached to the main unit and rotation was conducted at 25 rpm. Following 100 
revolutions (or 4 min), the tablets were removed from the device and cleaned to remove any excess 
powder or dust. These tablets were then weighed, analysed and compared to the initial weight for any 
loss, which should not exceed 1% (BP., 2016b). Equation 4 was used to calculate the percentage 
friability of tablets: 
Equation 4:   =>6	?
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Where, W1 is the initial weight or tablets weight before conducting the friability test 
W2 is the weight of tablets measured after testing was completed 
 
2.11. Scanning Electron Microscopy (SEM) 
Scanning electron microscopy (SEM) is commonly employed to investigate the morphological 
features of dry particles. In the present study, we used SEM to study the surface morphology of 
proliposome tablets. Prior to imaging, all samples were air dried on SEM stubs and gold coated with a 
sputter coater using a JFC-1200 Fine Coater (JEOL, Tokyo, Japan) for 2 min, followed by 
examination using an SEM instrument (Quanta-200, FEI) at 20 kV, and images were taken at various 
magnifications. 
 
2.12. Hydration and drug entrapment in liposomes 
Proliposome tablets (10 tablets) were triturated in a mortar using a pestle. The crushed proliposome 
tablets (300 mg) were subsequently weighed in a glass vial (25 ml) followed by hydration with 
aqueous solvent (10 ml) to form a liposome suspension (30 mg/ml, i.e. 30 mg of proliposome powder 
  
was dispersed in 1 ml of solvent media as a standard ratio). Liposome suspensions were then left for 
2 h at room temperature to anneal before determination of drug entrapment efficiency.  
Using deuterium oxide (D2O) as dispersion medium, a separation speed of 13,000 rpm (15,500 g) and 
time duration of 90 min using a bench centrifuge (using a Spectrafuge 24D, Jencons-PLS, UK) were 
applied to separate unentrapped (i.e. sedimented BDP crystals and the dissolved BDP in aqueous 
media) from liposome-entrapped fraction of the steroid. HPLC (Agilent 1200 HPLC instrument, UK) 
was used to quantify BDP in different distinct fraction formed (Khan et al., 2015, Khan et al., 2017). 
Deuterium oxide, also known as heavy water, was used in this study due to its established ability to 
facilitate the separation of free BDP crystals upon centrifugation based on the fact that steroid crystals 
have higher density than liposome vesicles; thus, upon centrifugation, the unentrapped drug crystals 
sedimented while liposome vesicles (incorporating a fraction of BDP) floated at the surface (Batavia et 
al., 2001, Khan et al., 2015, Khan et al., 2017). Preforming the separation experiments in 
conventional deionized water results in concomitant sedimentation of both free steroid crystals and 
liposomes incorporating the drug, justifying the employment of 'heavy water' (Khan et al., 2015, Khan 
et al., 2017). It is important to bear in mind that the use of the heavy water was confined to the 
entrapment investigations. BDP was assayed by employing a mixture of 75:25 (v/v) methanol and 
deionised water as the mobile phase at a flow rate of 1.7 ml/min, and 239 nm was used as the 
detection wavelength. The temperature was set and maintained at 40°C, with an injection volume of 
20 µl. The HPLC column used was a 150 mm X 4.6 mm, C-18, 5-micron column (Agilent technology, 
USA). 
 
2.13. Characterization of sorbitol-based proliposome tablets for stability purposes 
Sorbitol-based proliposome tablets in 1:15 w/w lipid to carrier ratios were selected for stability studies 
(based on investigation in the results sections). These proliposome tablets were hydrated to generate 
liposomes followed by characterization in terms of VMD (also referred as size analysis), SPAN 
(known as size distribution), zeta potential (surface charge), and drug entrapment efficiency. 
Furthermore, the tablets were checked against the established set of compendial QC tests (i.e. 
uniformity of weight, disintegration time, hardness and friability). A portion of freshly manufactured 
batches of sorbitol-based proliposome tablets in 1:15 lipid to carrier were tested and considered as a 
control (proliposome tablets). The remaining portions of each manufactured tablets batch (each in 
triplicate) were kept at fridge temperatures (FT; 6°C), room temperature (RT; 22°C) and high 
temperature (HT; 40°C) for a stability studies over a period of 18 months (i.e. 1, 2, 3, 4, 5, 6, 12 and 
18 month).  
VMD, also commonly known as median size or 50% undersize and SPAN (a term introduced  by 
Malvern Instrument software to express the polydispersity of the particles) of liposomes generated 
from sorbitol-based proliposome tablets in a 1:15 w/w ratio was determined by laser diffraction 
(Malvern Mastersizer 2000, Malvern Instruments Ltd., UK). Mathematically, SPAN was calculated by 
the instrument’s software; SPAN = (90% undersize - 10% undersize)/50% undersize 
  
Zetasizer Nanoseries (Malvern Instruments Ltd., UK) automatically calculates the zeta potential of 
liposomes. Liposome suspensions of 700 µl were transferred using a Gilson pipette (Gilson Pipetman, 
UK) into a cell made from polystyrene latex. The measurement temperature was adjusted at 25°C, 
and using Laser Doppler Velocimetry (LDV) the electrophoretic mobility of liposomes in dispersion 
was analysed. 
 
2.14. Statistical analysis 
Statistical analysis was performed on the data obtained using one-way analysis of variance (ANOVA) 
or Student’s t-tests by employing the SPSS software, to determine whether the difference is 
significantly different between more than two groups or two sets of data, respectively. All experiments 
were conducted in triplicate using three different batches and the level of significance in difference 
was chosen as p<0.05.  
 
3. RESULTS AND DISCUSSION  
3.1. Tapped density of proliposome powders 
Out of the coarse carbohydrate carriers investigated, sorbitol exhibited fair flowability (based on Carr’s 
scale of flowability) (Carr, 1965, BP., 2016d), with a compressibility index of 17.06 ± 0.14% and a 
Hausner ratio of 1.21 ± 0.01 (Table 1 and Table 2) (p<0.05), when compared to D-mannitol, which 
was comparatively found to exhibit very poor flow properties (i.e. a compressibility index of 34.78 ± 
2.03% and a Hausner ration of 1.53 ± 0.05) (Table 1 and Table 2).  
Coarse carbohydrate carriers were utilised as a control, in order to study the effect of lipid content on 
the carbohydrate carriers, and subsequently to investigate their influence on proliposome powder 
flowability for the purpose of tableting. Irrespective of formulation’s lipid to carrier ratio (i.e. 1:10 or 
1:15), the presence of BDP elicited no effect (p>0.05) on powder flow properties, as characterized by 
Carr’s scale of flowability. Consequently, proliposome powder formulations with drug were selected 
for comparison in the forthcoming discussion. 
Overall, the compressibility index and Hausner ratio, both indicated that the 1:10 lipid to carrier ratio 
formulations possessed a trend for better (p>0.05) flow properties for both carriers; in comparison to 
formulations at 1:15 w/w lipid to carrier ratio. Higher flowability of powder is expected to allow for 
improved filling of the die; and hence, upon compression, tablet weight uniformity is likely to be 
improved. In order to further understand the differences in powder flow properties between the 
formulations studied; the lipid content in each formulation was analysed by the Stewart assay 
(Stewart, 1980). The assay results confirmed that the 1:10 w/w ratio formulations had higher lipid 
concentrations than the 1:15 w/w ratio (Table 3), indicating that high lipid incorporation in the slurry 
resulted in successful coating of the carbohydrate particles. The higher lipid content was deemed to 
be responsible for causing powder particles to be more coherent, thus increasing resistance to flow 
  
and preventing adequate compaction during tapping of the proliposome powders. This would explain 
the lower compressibility index values via tapped density observed for the higher lipid content 
formulations (i.e. 1:10 lipid to carrier), when compared to proliposomes with lower lipid content (i.e.  
1:15 lipid to carrier) (Table 2). The reduction in lipid content in the latter formulation is associated with 
an increased in void spaces between the particles. 
 
3.2. Angle of repose of proliposome powder formulations 
On comparison of the investigated formulations, a number of notable differences were observed in 
terms of angle of repose (AOR). Firstly, it was noted that the incorporation of BDP had insignificantly 
affected the AOR of the proliposome formulations (p>0.05), consequently, only BDP containing 
formulations were discussed in detail. 
The AOR values of sorbitol-based BDP incorporated formulations in 1:10 and 1:15 lipid to carrier 
ratios were 26.61 ± 0.08° and 25.62 ± 1.08°, respectively, and were found to be significantly lower 
(p<0.05) than AOR for coarse sorbitol powder (28.33 ± 0.38°). All values for sorbitol-based 
proliposome formulations were found to be within the range of 25 - 30° (Table 1 and Table 2), 
indicating ‘excellent’ flowability. Anh and Kathleen (2001) have reported that particle size of sorbitol is 
responsible for its flowability and suitability for direct compression. The excellent flowability observed 
using sorbitol may be therefore attributed to the morphology of the particles. Sorbitol is well noted for 
being irregular to spherical in shape, identifying it as a carrier with unique flowability. 
In addition to its shape, sorbitol particle surfaces are noted to possess protruding needles, owing to its 
high porosity (Newman et al., 1999, Khan et al., 2017), which may prevent particle agglomeration and 
provide void spaces. This is potentially due to the ability of these porous structures to accommodate 
the lipid phase within proliposome formulations, hence stickiness between adjacent particles is 
minimized (Payne et al., 1986b), resulting in preserved flowability upon coating with lipids (Ahn et al., 
1995, Elhissi et al., 2011). Sorbitol-based proliposome formulations at a 1:15 lipid to carrier ratio 
demonstrated highest flowability (AOR = 25.62 ± 1.08°). Literature findings indicate that powder 
flowability is highly influenced by size, shape and bulk density of the particles (Liu et al., 2012, Saw et 
al., 2013, Szalay et al., 2015), agreeing with our AOR studies for sorbitol-based proliposome powder 
(Table 2).  
By contrast, D-mannitol-based proliposome powder exhibited the highest AOR values, ranging from 
40.88 ± 0.56° and 40.02 ± 0.51° for 1:10 and 1:15 lipid to carrier ratios; to 43.78 ± 1.30° for coarse D-
mannitol. On categorization of these values using Carr’s indicator for powder flow properties, D-
mannitol demonstrated ‘passable’ or ‘adequate’ flowability (Table 2 and Table 1) (Carr, 1965). Again, 
morphology of the coarse carbohydrate carrier particles was found to be an influential factor on 
powder flow. The crystalline oblong shape of D-mannitol has been reported to be the reason behind 
for the compromised flow of this powder (Yan-yu et al., 2006, Khan et al., 2017). 
  
In addition to particle morphology which is agreed to be a prime factor influencing powder flowability, 
the lipid content of the proliposome powder formulations was believed to be another influential factor. 
The reduction in lipid content may cause a trend for decrease in AOR, but that, however, was not 
significant statistically (p>0.05) (Table 2 and Table 1). As the quantity of carbohydrate carrier is 
increased in 1:15 lipid to carrier formulation, the lipid may spread more thinly and uniformly over the 
carrier particles, reducing particle-particle coherence, offering an explanation for the trend of AOR 
reduction. 
The particle size of coarse sorbitol carrier was in the range of 250-700 µm, whereas the particle size 
of coarse D-mannitol was <250 µm. Sorbitol particles are spherical in terms of shape and thus 
exhibited better flow properties. Moreover, as the particle size distribution is uniform, this in turn offers 
minimal weight variation between sorbitol-based proliposome tablets (due to uniform filling of 
tabletting machine die) (Khan et al., 2017). D-mannitol particles are crystalline/oblong in terms of 
morphology and irregular in terms of size distribution, thus associated flow properties are poorer (as 
indicated by high values of angle of repose). 
Significant differences (p<0.05) in AOR values were observed between sorbitol and D-mannitol-based 
proliposome formulations (Table 2). Sorbitol was identified as a more flowable proliposome powder 
(when compared to D-mannitol-based formulations), which can be expected at this stage of the 
investigation to produce tablets with more favourable characteristics in terms of appearance, 
hardness, weight variation and disintegration time. These characteristics represent a prime focus of 
the subsequent sections. 
 
3.3. Selection of proliposome powder formulations for tablet manufacturing 
During tablet manufacture, sorbitol-based proliposome powders at the ratio of 1:10 w/w, and D-
mannitol-based proliposome powder in a 1:10 and 1:15 w/w ratio exhibited sticking to the punches 
and die during tableting. This might be attributed to the higher lipid content in D-mannitol-based 
proliposome powder (Table 3). The lipid phase forms an amorphous coating over the carbohydrate 
particles individually to form proliposome powder. Previous reports have shown that during tabletting, 
higher lipid content (e.g. mineral oil) may reduce interlocking of particles (e.g. weakening particle 
bonding/deformation) during the tabletting process i.e. there is increased resistance to compaction 
force with rising the lipid concentration, potentially resulting in a reduction in tablet strength (Moody et 
al., 1981, Roberts et al., 2004). Hydrophobic additives in tablet formulations (such as magnesium 
stearate) may also influence the flow and compaction properties at excessively high concentrations; 
these additives may resist compaction whereas at suboptimal concentrations flow properties are not 
influenced sufficiently to promote die filling (Roberts et al., 2004, Rana and Kumar, 2013). The lipid 
coating on the proliposome particles is also hydrophobic, thus when not optimised, may mirror some 
of the properties discussed (i.e. reducing compaction properties). Hence automated tablet 
manufacturing with the aforementioned ratios and formulation was not possible. Contrastingly, at a 
lower lipid concentration (i.e. 1:15 lipid to carrier ratio for sorbitol carrier) (Table 3), the proliposome 
  
powder did not preclude the automated manufacture of proliposome tablets (i.e. 20 ± 4 tablets per min 
with compression force of 3.00 - 4.50 kN), facilitating the manufacture of tablets at this ratio. 
Due to stickiness associated with sorbitol-based proliposome in a 1:10 ratio, and D-mannitol-based 
proliposome formulations for both ratios (i.e. 1:10 and 1:15), the manufacture of tablets from these 
formulations was conducted manually rather than automatically. 
 
3.4. Surface morphology characterization of proliposome tablets using SEM 
SEM was employed in this study to examine the surface morphology of the proliposome tablets. 
Comparisons of BDP-containing and BDP-free tablets had no difference in surface morphology, 
indicating that BDP did not apparently affect the morphology of tablet surfaces.  
Upon SEM examination of sorbitol-based proliposome tablets (1:10 w/w), the surface morphology 
exhibited the presence of fissures (Figure 1a). These were attributed to the higher lipid content which 
would result in resistance to the compaction force during tabletting. At the 1:15 w/w lipid to carrier 
ratio (Figure 1b), sorbitol-based proliposome tablets elicited lower roughness in terms of fissures on 
the surface of tablet. The low proportion of lipid to sorbitol carrier in the formulation was also 
confirmed using the Stewart assay (Table 3). Moreover, tablet surface did not elicit protruding needles 
of sorbitol when prepared using 1:10 or 1:15 lipid to carrier powder. The reduced lipid content in 
proliposome particles may have facilitated the compaction of the proliposome powder, without 
causing stickiness of the particles to the punch surface. 
When D-mannitol carrier was used, differences in the surface appearance of the tablets in 
accordance to using different lipid to carrier ratio was evident (Figure 1c and 1d). D-mannitol-based 
tablets in 1:10 w/w were found to adhere to the punches and die; this is supported by SEM images 
which illustrated the presence of crystals and scattered lipid on the D-mannitol tablet surfaces. D-
mannitol-based proliposome tablets using the 1:15 lipid to carrier ratio were found to exhibit smoother 
surfaces (Figure 1d) compared to tablets manufactured using 1:10 ratio (Figure 1c), which is again 
attributed to the lipid content in the formulation (i.e. lower lipid content resulted in less adherence of 
proliposome particles to the surfaces of die and punches). 
In terms of compaction, SEM illustrated that sorbitol-based proliposome powders demonstrated 
improved compaction compared to D-mannitol-based proliposome formulations. Examination of 
tablets indicated that sorbitol particles exhibited higher deformability upon compaction, possibly due to 
their porous nature. Contrastingly, D-mannitol was deemed to retain (i.e. do not undergo major 
changes) its crystalline structure upon compaction (Koner et al., 2015). A reduction in lipid content 
(i.e. 1:15 w/w ratio formulations) was proposed to result in smoother proliposome tablets, formed from 
both sorbitol and D-mannitol-based tablets at the ratio of 1:15 lipid to carrier. Proliposome tablets 
were manufactured for both ratios and carriers and were further characterized.  
 
  
3.5. Uniformity of weight of proliposome tablets 
Sorbitol-based proliposome tablets were prepared in a weight that was found to be ranging between 
90.17 ± 4.30 mg and 91.97 ± 2.81 mg for both lipid to carrier ratios (with or without BDP) (Table 4). 
Similarly, D-mannitol-based proliposome tablets in 1:10 and 1:15 lipid to carrier ratios were prepared 
(i.e. with or without BDP) in weight that ranged between 91.44 ± 4.21 and 92.16 ± 3.60 mg (Table 4). 
The tablet weight deviation range was set at ± 7.5% (for the 80 - 250 mg weight range of tablets), with 
not more than two tablets permitted to deviate from the average weight and none deviating by more 
than twice that percentage (BP., 2016e). In sorbitol-based proliposome formulations, only two tablets 
exhibited deviation from the average weight by ± 7.5%. Of the two tablets found, each belonged to 
each respective ratio (i.e. 1:10 and 1:15 w/w), falling in the acceptable range according to BP 
standards (i.e. no more than two tablets deviating in each batch from the average tablet weight) (BP., 
2016e). Thus, both batches of sorbitol-based proliposome tablets were deemed to have passed 
weight variation testing. 
Comparatively, in D-mannitol-based proliposome tablets, four tablets demonstrated a deviation of ± 
7.5% in weight for the 1:10 w/w D-mannitol formulations (four tablets each of BDP incorporated 
tablets and BDP free tablets). Contrastingly, only one tablet showed deviation in excess of ± 7.5%, for 
the 1:15 w/w D-mannitol tablet formulation (i.e. without BDP). Tablet weight variation within the 
accepted range (i.e. sorbitol-based proliposome tablets in a 1:10 and 1:15 w/w lipid to carrier ratio), 
can indicate uniform distribution of lipid during proliposome powder preparation (using the Slurry 
method). This was also demonstrated by the AOR values for powder flow properties. AOR values for 
sorbitol-based powders suggested an ‘excellent’ flow properties for both lipid concentrations (1:10 and 
1:15), whilst ‘fair’ flowability for D-mannitol-based proliposome powders was observed (Table 2 and 
Table 1). 
 
3.6. Disintegration test of proliposome tablets 
Sorbitol tablets manufactured from proliposome powders in a 1:10 lipid to carrier (with or without 
BDP), exhibited an average disintegration time of 8.67 ± 0.88 min and 10.04 ± 0.73 min, respectively 
(Figure 2a). Similarly, sorbitol-based tablets with 1:15 lipid to carrier ratio showed no significant 
difference (p>0.05) between formulations containing BDP (i.e. disintegration time was 5.85 ± 0.66 
min), and those without BDP (i.e. disintegration time was 6.15 ± 0.48 min) (Figure 2a). This indicated 
that, when sorbitol carrier was used, the presence of BDP did not significantly affect the disintegration 
time of the tablets for each lipid to carrier ratio investigated. 
On comparison of sorbitol-based proliposome tablets made from 1:10 and 1:15 lipid to carrier ratios, a 
statistically significant difference (p<0.05) was observed, with shorter disintegration time noted for the 
latter formulation. As lipid content is the sole varying factor for each carrier type, it is suggested that 
lipid content is the only parameter that may affect the disintegration time. Higher lipid content may 
produce proliposome tablets with higher surface hydrophobicity, which may resist water penetration 
and prolong the time needed for complete tablet disintegration (Uzunovic and Vranic, 2007). 
  
Moreover, a significant difference (p<0.05) was observed in the disintegration time for D-mannitol 
formulations, exhibiting a higher disintegration time of 13.60 ± 0.45 min for 1:10 formulations when 
compared to 10.53 ± 1.16 min for 1:15 formulations (Figure 2a). This further confirmed that high lipid 
content was the major influential factor at extending the disintegration time of proliposome tablets. 
Surface characteristics (SEM in Figure 1) may correlate with tablet disintegration characteristics, as 
the surface morphology heavily influences the behaviour of proliposome tablets in a given dispersion 
medium. The higher lipid content in the 1:10 w/w ratio offers an explanation behind the extended 
disintegration time of the tablet, compared to those manufactured using the 1:15 lipid to carrier. 
Moreover, upon direct comparison between both carriers, a significant difference was observed in 
terms of disintegration time (p<0.05), suggesting that carrier selection also plays a pivotal role in the 
disintegration time of proliposome tablets (Ohrem et al., 2014).  
In summary, sorbitol was found to be the superior carrier for proliposome tableting, particularly upon 
using lower lipid content (i.e. at a ratio of 1:15 lipid to carrier). It was observed by Zhao and 
Augsburger (2005) that after fragmentation of a tablets in general, tablets allow a quick release of a 
drug and subsequent bioavailability.  
 
3.7. Hardness testing (Crushing strength) of proliposome tablets 
Sorbitol-based proliposome tablets made from 1:15 lipid to carrier (with or without BDP), showed a 
trend of higher, yet statistically insignificant (p>0.05) crushing strength; when compared to 
proliposome tablets made from the 1:10 w/w ratio formulations (Table 4). D-mannitol-based 
proliposome tablets at both ratios (1:10 and 1:15), were unable to withstand the crushing strength of 
the hardness tester, showing poor hardness. This may be associated with the fact that coarse 
mannitol powder has low compressibility (Mizumoto et al., 2005). Moreover, despite the poor 
hardness exhibited by D-Mannitol-based proliposome tablets, they presented longer disintegration 
times (Figure 2a), when compared to sorbitol-based proliposome tablets, indicating softness of the D-
mannitol-made tablets and poor penetration of water through these compacted particles. D-mannitol 
D-mannitol particles were observed to be oblong/ellipse in shape  (Khan et al., 2017) and therefore 
resisting compaction (i.e. retained crystallinity), giving rise to low tablet hardness. A similar 
compression force was employed for sorbitol formulations which conversely exhibited high 
compactability (i.e. due to high particle deformability) giving rise to high hardness values (Koner et al., 
2015). Difference in hardness may suggest that the compression force has changed the sorbitol 
particles plastically, whereas the D-mannitol particles retained their shape with some fragmentation 
during compression in the presence of lipid in the formulations. Whilst both formulations exhibited 
differences in terms of compaction, disintegration times, both were within the acceptable limits (BP., 
2016a). Differences observed in disintegration time may further be attributed to carrier solubility. D-
mannitol tablets exhibited poor hardness, thus tablets disintegrated relatively ~15 min disintegration 
time. Contrastingly, although sorbitol-based tablets exhibited high hardness, its water solubility (2350 
mg/ml) is circa 20 fold greater than D-mannitol (100 mg/ml) (Section 2.1), resulting in a similar 
  
disintegration time (~10 min) i.e. in D-mannitol formulations poor hardness was the overriding factor 
for short disintegration times; and in sorbitol formulations, its exceptionally high water solubility was 
responsible for a short disintegration time despite high tablet hardness. 
Literature findings indicate that the porosity of sorbitol particles may facilitate their ability to pack well 
upon compression due to their high moulding properties (Sastry et al., 2000, Mizumoto et al., 2005), 
coming in agreement with the findings in our study using sorbitol-based proliposome tablets.    
 
3.8. Friability studies 
Upon analysis, sorbitol-based proliposome tablets (BDP incorporated) demonstrated a significantly 
(p<0.05) lower friability (0.17 - 0.19%), when compared to D-mannitol-based proliposome tablets 
(0.24 - 0.42%) (i.e. irrespective of the lipid to carrier ratio) (Figure 2b). Additionally, tablets produced 
from sorbitol-based proliposome powders were found to be harder than D-mannitol-based tablets 
(Figure 2b). This may be attributed to the ability of sorbitol-based particles to deform more readily 
upon compaction, due to their porous nature (Khan et al., 2017). Tablets possessing high levels of 
hardness are known to exhibit lower friability (Desai et al., 2014), which came in agreement with our 
proliposome tablet findings (Table 4). 
Differences between sorbitol-based proliposome tablets at lipid to carrier ratios of 1:10 and 1:15 were 
found to be statistically insignificant (p>0.05), showing friability values of 0.17 ± 0.03% and 0.19 ± 
0.06% for the 1:10 w/w ratio formulation (with and without BDP respectively); and values of 0.20 ± 
0.03% and 0.19 ± 0.05% in the 1:15 lipid to carrier tablets (with and without BDP respectively). D-
mannitol-based Proliposome tablets (Table 4), were found not to be able to withstand the force 
applied by the hardness tester, yet still exhibiting a longer disintegration time and greater friability than 
sorbitol-based proliposome tablets (Figure 2a and 2b).  
A significant difference (p<0.05) was found in terms of friability for D-mannitol-based proliposome 
tablets at a 1:10 lipid to carrier, when BDP was incorporated or omitted (i.e. 0.42 ± 0.04% and 0.24 ± 
0.04%), showing higher friability for tablets containing BDP. By contrast, upon using the lower lipid 
content tablets (i.e. 1:15 lipid to carrier), only an insignificant trend (p>0.05) of higher friability in BDP-
containing tablets was observed (0.37 ± 0.07% with BDP and 0.3 ± 0.09% without BDP), indicating 
that the steroid would make the tablets more friable only when high lipid concentration in proliposome 
powders are used.   
Overall, the crushing strength of conventional tablets is directly proportional to the force of compaction 
used. Additionally, excessive force of compaction may not further increase the tablet hardness, in 
contrary, it may even result in promoting tablet friability (Perioli et al., 2008). However, higher friability 
in D-mannitol-based proliposome tablets in lipid to carrier ratios investigated, can possibly be 
attributed to the tendency of D-mannitol to retain (do not undergo major changes) its crystalline shape 
(Koner et al., 2015). Additionally, D-mannitol crystals were also found on the tablet surface, 
suggesting fragility of the tablets (Figure 1c). 
  
In summary, on investigation of tablet friability, tablets prepared from sorbitol-based proliposomes 
showed the lowest loss during friability testing, particularly when using 1:15 w/w lipid to carrier ratio.  
 
3.9. Entrapment efficiency of BDP in liposomes generated from proliposome tablets 
Liposomes generated via hydration (Section 2.12) from sorbitol-based proliposome tablets with 1:10 
and 1:15 lipid to carrier ratios, exhibited drug entrapment efficiencies of 53.82 ± 6.42% and 57.43 ± 
9.12%, respectively. Hence, steroid entrapment efficiencies in liposomes generated from sorbitol-
based proliposome tablets were independent of lipid to carrier ratio (p˃0.05) (Figure 3). Similarly, lipid 
to carrier ratio did not affect BDP entrapment by vesicles generated from D-mannitol-based 
proliposome tablets (p>0.05), being 39.90 ± 4.30% and 35.22 ± 6.50% for 1:10 and 1:15 lipid to 
carrier formulations, respectively. Furthermore, no significant difference (p˃0.05) was also found with 
respect to un-entrapped BDP (i.e. free BDP crystal sedimented and dissolved BDP in aqueous media, 
post centrifugation) (Khan et al., 2015, Subramanian et al., 2016, Khan et al., 2017). Upon 
comparison, no significant difference was found for the un-entrapped BDP for sorbitol-based 
proliposome tablets in both 1:10 and 1:15 lipid to carrier ratios (46.18 ± 7.29% and 42.58 ± 8.77%). A 
similar trend was observed for the D-mannitol-based proliposome tablets at the 1:10 and 1:15 lipid to 
carrier ratios, in terms of un-entrapped BDP (60.11 ± 4.46 % and 64.78 ± 7.35%) (Figure 3). 
Upon comparison of sorbitol and D-mannitol-based proliposome tablets; entrapment efficiency was 
found to be greater for sorbitol-based tablet formulations. In addition, both 1:10 and 1:15 formulation 
ratios prepared from sorbitol-based tablets exhibited a significantly (p<0.05) high entrapment of BDP 
when compared to D-mannitol-based formulation ratios. The higher entrapment efficiency may be 
explained by the porous nature of sorbitol (Khan et al., 2017), which allows uptake of the lipid 
constituents into the larger surface area offered by void spaces of the sorbitol particles. As it is 
mentioned, the entrapment efficiency is associated with the porous structures of the carrier. What is 
meant by this is that to our understanding, there is a difference in final lipid concentration following 
tabletting, which in turn influences the final entrapment efficiency. As mentioned (Figure 1), due to its 
structure, sorbitol may retain lipid content within the porous structure of the carrier during tabletting, 
thus lipid is accommodated within the porous structures of the carrier during compaction. 
Contrastingly, D-mannitol’s crystalline shape and lack of porosity means that surface lipid 
concentration prior to tabletting is high and an amount of the lipid is lost by sticking to the die and 
punch of the tablet press, which is indicated by tablet picking (Figure 1). This reduction in lipid content 
using D-mannitol means there is less lipid available in the D-mannitol-based proliposome tablets to 
facilitate drug entrapment, resulting in lower entrapment efficiencies. Thus, sorbitol is identified as a 
highly appropriate carbohydrate carrier for manufacturing proliposome tablets. 
 
  
3.10. Stability studies of proliposome tablets 
Based on the aforementioned results and discussion, sorbitol-based proliposome tablets in 1:15 ratio 
were selected for stability studies over a period of 18 months. Sorbitol-based proliposome tablets 
appeared to be white in colour upon manufacture, and the lipid phase looked uniformly distributed 
over the particles (Figure 4a). After 18 months of storage of tablets at FT temperature, the white 
colour of the tablets did not apparently change (Figure 4b). Contrastingly, the colour of sorbitol-based 
proliposome tablets stored at RT temperature changed to light yellow (Figure 4c), which commonly 
indicates phospholipid oxidation; this yellowish appearance was more prominent when tablets were 
stored under HT conditions (Figure 4d). Manjula et al. (2014) reported a discoloration of proliposome 
powder (prepared using a traditional method) after 90 days, when proliposome powder was kept at 
45°C. Slurry-based proliposome tablets behaved similarly in response to using high temperature. 
  
3.11. Liposome size and size distribution during stability studies 
Upon direct comparison between various temperature conditions and also in comparison to control 
tablets (when proliposome tablets were freshly prepared), a significant increase in size (expressed as 
volume median diameter; VMD) was observed for liposomes (generated upon hydration of sorbitol-
based proliposome tablets), when the duration of stability period was extended to 18 months (Figure 
5a). At FT, the VMD of liposomes increased from 5.97 ± 0.38 µm (month 1) to 7.13 ± 0.99 µm (18 
month). No significant difference (p>0.05) was found for VMD between each month upon comparison 
with the control sample (i.e. 5.90 ± 0.70 µm), however only a trend for increase in liposome size was 
observed due to temperature difference. By contrast, when tablets were kept at RT, VMD of 
liposomes significantly increased (p<0.05) from 5.90 ± 0.70 µm (i.e. for control sample) to 8.45 ± 0.59 
and 11.98 ± 0.57 µm for 12 and 18 month, indicating vesicle aggregation and / or fusion upon 
hydration. Moreover, upon direct comparison of VMD of liposomes between RT and FT, size of 
liposomes stored at RT was found to be significantly larger than that measured for tablets stored at 
FT for month 6, 12 and 18 (Figure 5a). Liposomes hydrated from sorbitol-based proliposome tablets 
stored at HT (i.e. in 1:15 w/w ratio), exhibited a consistent increase in VMD from month 4 throughout 
to month 18. Thus, the VMD reached 14.79 ± 0.79 µm at month 18 (VMD for control sample was 5.90 
± 0.70 µm). 
Storage at HT was suggested to be responsible for the discoloration of proliposome tablets (Figure 4), 
because of possible degradation of the lipid component via oxidation (Torchilin and Weissig, 2003). 
Phospholipid degradation at elevated temperature using proliposome powder has been documented 
in previous research, corroborating findings of our present report (Manjula et al., 2014, Prasad et al., 
2014). 
SPAN of liposomes generated from the control tablets were compared with liposomes generated from 
each of the monthly set of tablets for the 18 month stability period (Figure 5b). Upon analysis of the 
SPAN values generated from formulations stored at FT, no significant difference (p>0.05) was noted 
  
for any of the stored samples when direct comparison was made with the control sample (3.14 ± 0.55) 
(Figure 5b). Similarly, no significant difference (p>0.05) in SPAN values was exhibited by RT stored 
formulations, when compared to the control sample. Contrastingly, a significant increase (p<0.05) in 
SPAN values were observed at HT for months: 5, 6, 12 and 18 (4.32 ± 0.29, 4.85 ± 0.86, 5.15 ± 0.78 
and 5.28 ± 0.56), when compared to the SPAN values of control sample (3.14 ± 0.55) (Figure 5b). 
However, towards the latter months of stability period, SPAN was observed to notably increase in the 
HT conditions (Figure 5b), i.e. exhibiting a statistically significant difference (p<0.05) when compared 
to SPAN values of FT and RT stored formulations. High SPAN measurements commonly indicate 
particle aggregation. Previous research has indicated that high temperature and physical instability (of 
lipid component) may cause liposome fusion or aggregation, resulting in larger liposomes as well as 
potential degradation of the concentric bilayers in liposomes (Lasic, 1998, Jain, 2012). This 
phenomenon (degradation and increased VMD and SPAN) was clearly illustrated by the extended 
stability studies in figure 5a. Phospholipid integrity was kept to a maximum when samples were stored 
at FT. 
 
3.12. Zeta potential of liposomes during stability studies 
For gaining knowledge on the surface properties of liposome vesicles generated upon hydration of 
proliposome tablets, we conducted a zeta potential analysis on the vesicles, using the same storage 
protocol employed in the previous section. For tablets stored at FT conditions, a statistically significant 
difference (p<0.05) was observed when comparing the samples stored at month 6, 12 and 18 (i.e. -
3.99 ± 0.25, -5.45 ± 0.19 and -6.22 ± 0.15 mV, respectively) with the control sample (-3.08 ± 0.26 mV) 
(Figure 5c). A general trend of increase in the negativity of zeta potential values with storage time was 
found; this increase was substantially higher in the latter months of stability testing. With respect to 
samples stored at RT, differences (p<0.05) were observed between the control sample (-3.08 ± 0.26 
mV) and samples from months 5, 6, 12 and 18 (-4.00 ± 0.22, -6.31 ± 0.27, -7.03 ± 0.29 and -8.47 ± 
0.18 mV), exhibiting higher zeta potential values than control sample (Figure 5c). Additionally, 
measurements conducted in months 5, 6, 12 and 18 (i.e. for RT) were found to be significantly higher 
(p<0.05) to the alternate months tested (i.e. 1, 2, 3 and 4); these values of zeta potential (i.e. months 
5, 6, 12 and 18 at RT) were also higher when compared to the samples stored at FT (i.e. for the same 
months of 5, 6, 12 and 18). Again a raised zeta potential was observed for the latter months, which 
possibly indicates that under the RT storage conditions the lipid component is stable for the initial four 
month storage period (Figure 5c). 
Proliposome tablets stored under HT (after hydration into liposome suspension) were found to exhibit 
a stronger trend in terms of increasing zeta potential in comparison to the control sample, as well as 
to the samples stored in FT and RT. Initially, a statistically significant difference (p<0.05) was noted 
between the control sample (-3.08 ± 0.26 mV) and samples from months 3, 4, 5, 6, 12 and 18 (-4.52 ± 
0.17, -6.39 ± 0.40, -6.84 ± 0.13, -7.93 ± 0.25, -8.68 ± 0.31 and -11.97 ± 0.26 mV respectively) showed 
a higher zeta potential under HT storage condition (Figure 5c). Similarly, higher zeta potential values 
  
were also found for the same months (i.e. 3, 4, 5, 6, 12 and 18) to the zeta potential of both samples 
stored at FT as well as RT (p<0.05). 
Overall, irrespective of the storage conditions, zeta potential was found to increase over time, this was 
observed to be more drastic following the third month of storage at HT, and sixth month of storage for 
RT and FT. Linked with the discolouration of tablets (Figure 4), this further supports the suggestion 
that lipid component has degraded with time. Oxidation of double bonds (catalysed by metal 
impurities) of the hydrocarbon chain present in lipid molecules may be accelerated by heat and light, 
producing free radicals (Klemchuk, 2000). The addition of an oxygen molecule usually occurs at a 
carbon next to a double bond producing hydroperoxides, which are not stable and therefore 
decompose into aldehydes or carboxylic acids (also cause rancidity) (Frankel, 2005, Gueraud et al., 
2010). Deprotonation of these carboxylic acids (i.e. removal of H+) results in the formation O- groups, 
increasing overall negative charge. Moreover, hydrolysis of fatty acids  and sugars (e.g. 
disaccharides) may occur at both acidic and basic pH, this process is further supported by the 
presence of impurities (e.g. metal ions) which can cause an increase in polar units (Burgess, 1978, 
Richens, 1997). The unsaturated bonds in the presence of heat, may facilitate oxidation and the 
conversion of double bonds into hydroxyl groups in the hydrocarbon chain (Klemchuk, 2000). The 
presence of alkaline pH may further cause deprotonation, again increasing negative charge. SPC (i.e. 
phospholipid) employed in the formulation was of 94% purity (Section 2.1), the unaccounted 6% of the 
formulation may be comprised of metal ions and other substances which may impact the 
aforementioned processes. 
Further studies would attempt to identify the cause of lipid degradation; a potential cause may be 
oxidation of the lipid components resulting in discoloration under HT storage conditions (Torchilin and 
Weissig, 2003). 
 
3.13. Proliposome tablets characterization during storage 
Comparisons in terms of weight uniformity, disintegration time, crushing strength and friability of 
tablets were made between each month (under each set of storage conditions i.e. FT, RT and HT) for 
the entire 18 month duration, as well as with a control batch of tablets. 
Upon direct comparison of the control sample with each month sample at each condition (i.e. FT, RT 
and HT), no significant difference (p>0.05) was observed in terms of weight variation, hardness and 
friability between the batches (Table 5). This indicated that weight and strength of tablets remained 
relatively constant and stable irrespective of the storage time or temperature. In disintegration testing, 
upon examination of the FT stored samples at various monthly intervals, no significant difference 
(p>0.05) was found between the control sample and any of the monthly tested sample stored at FT. 
The same results were found for tablets stored at RT condition, with only exception of 18 month, 
exhibiting lower disintegration time of 3.97 ± 0.32 min compared to the control proliposome tablets 
(5.85 ± 0.66 min) (Table 5). Upon comparison of HT stored tablets, a statistically significant difference 
(p<0.05) was found between samples tested at months 6, 12 and 18 (3.79 ± 0.55, 3.46 ± 0.63 and 
  
3.06 ± 0.71 min) exhibited lower disintegration time than the control sample (5.85 ± 0.66 min) (Table 
5). 
The variance in disintegration time over an extended period, suggests that disintegration time is not 
stable throughout storage under HT conditions, particularly for the latter months. However, it is 
noteworthy that the degree of change in time is relative, and the disintegration conforms well with BP 
guidelines for uncoated standard tablets, even though it has seen to decrease over time (Table 5). 
Shorter disintegration time in traditional contexts is not perceived as a disadvantage; however at the 
present investigation where materials liable to degradation such as phospholipids are incorporated, 
the rapid disintegration indicates a change in the chemical structure or physical form of the tablet 
constituents, supporting the earlier size and zeta potential findings. 
Potentially, storage at the elevated temperature may also affect the lipid content on the proliposome 
tablets, resulting in decreased disintegration time. This may be attributed to the degradation of the 
lipid component, which in turn may reduce the hydrophobicity of the tablet, hence reduce 
disintegration time. 
 
3.14. Entrapment efficiency of BDP during stability 
Entrapment efficiency was investigated earlier in section 3.9 in order to determine the proportion of 
drug that is available to provide a gradual release from the vesicles. It is important also to study 
whether various storage temperatures can affect the proportion of steroid that will be entrapped upon 
hydration of the tablets. No significant difference (p>0.05) in entrapment efficiency was observed 
upon comparing of the FT stored formulations for six months with the control sample, indicating that 
entrapment at this temperature did not compromise the amount of drug that is available to provide 
controlled release. However, the entrapment significantly (p<0.05) decreased to 41.18 ± 4.96 and 
38.66 ± 3.09% for 12 and 18 month to the control sample (57.43 ± 9.12%) (Figure 5d); this trend was 
mirrored by RT stored samples. Again, the entrapment of BDP decreased to 42.14 ± 5.18 and 34.68 ± 
2.58% for 12 and 18 month when compared to the control tablets (57.43 ± 9.12%) (Figure 5d). This 
indicated that proliposome tablets stored at FT and RT retained good stability for six months in terms 
of entrapment efficiency, but the extended stability period (i.e. after six months) resulted in a reduction 
in entrapment of BDP. Proliposome tablets stored under HT conditions, exhibited a significant 
difference in entrapment efficiency of BDP after three months to the entrapment efficiency 
demonstrated by the control sample. A significant (p<0.05) drop in entrapment was observed for the 
latter months for tablets stored at HT conditions. The entrapment efficiency gradually reduced from 
57.43 ± 9.12% of the control sample to 32.56 ± 5.47, 32.03 ± 4.57, 29.30 ± 3.63, 25.13 ± 6.22 and 
17.93 ± 5.37% respectively, for months 4, 5, 6, 12 and 18 (Figure 5d). This trend of lower entrapment 
was also exhibited by the sample stored at HT storage conditions to the tablets stored at FT as well 
as RT. Moreover, BDP exhibited a retention time of 3.76 min for all the sample investigated (i.e. for 
control sample as well as sample stored for 18 months at different temperature conditions). 
  
The lower entrapment values obtained for the FT, RT (after 6 months) and HT stored samples at 
month 4, 5, 6, 12 and 18 may be explained by potential degradation of the lipid over storage condition 
for extended period of time. Potential degradation in the lipid may subsequently resulted in a lower 
concentration of liposome generation in the dispersion medium and as a consequence, a lower 
entrapment efficiency of BDP achieved. This is supported by Gupta et al., (2008) using proliposome 
powders, who reported that lower lipid concentrations would result in lower entrapment efficiencies 
(Gupta et al., 2008). Moreover, temperature above the phase transition temperature of the lipid is 
believed to cause destabilization in the lipid content, resulting in drug leakage from the liposome 
vesicles and consequently lower the entrapment efficiency (Lasic, 1998). Another study conducted by 
Kurakula et al., (2012) utilising prednisolone in proliposome powder formulations manufactured using 
particulate-based proliposome method, exhibited that samples stored at elevated temperatures as 
well as low temperatures (i.e. freezing) were found to insignificantly (p>0.05) affect the entrapment 
efficiency, for up to a period of three months (Kurakula et al., 2012), agreeing with our findings (for a 
period of three months). However, this research has conducted stability testing for a period of 18 
months, as opposed to 3 months, and we showed a significant drop in stability following 3 months 
storage (HT storage conditions). 
In an additional study where proliposome powder formulations were stored at varied temperatures 
(i.e. 8, 25, 37 and 45°C) for 90 days (Manjula et al., 2014), it was observed that following 90 days, 
proliposome powders stored at 8 and 25°C were stable in terms of physical appearance (e.g. colour) 
and also the entrapment of the incorporated drug Fenoprofen. Notably, proliposome colour changed 
and the entrapment efficiency dropped by 12% at the third month for the sample stored at 45°C. 
Elevated temperature may  be responsible for lipid degradation (Manjula et al., 2014). In the present 
research, the change in colour of the sorbitol-based proliposome tablets was observed at month 6 
and onwards (clear discoloration for tablets stored at HT, less discoloration for RT and minor 
discoloration for FT), this may potentially indicate degradation in the lipid component, which is also 
supported by lower entrapment values at 6 months (Figure 5d). In another study, proliposome 
powders formulated with naproxen, storage at 40°C for three months resulted in a reduction of 
entrapment efficiency, further highlighting the deleterious effect of elevated temperatures on 
proliposome formulations. In that study, it was proposed that drug leakage at the elevated 
temperature was responsible for the lower entrapment values observed, and that storage at 8°C may 
minimized this effect (Prasad et al., 2014). 
Our investigation is the first one of its kind that utilized proliposomes prepared using a slurry approach 
to manufacture tablets that were thoroughly characterized and subjected to a prolonged stability study 
at various temperatures. The forthcoming publications will be on the delivery options of proliposome 
tablets using steroids and possibly other drugs.  
 
4. CONCLUSIONS 
  
Sorbitol was identified as the most appropriate carbohydrate carrier for proliposome powder 
formulation, when used in a 1:15 w/w lipid to carrier ratio, due to its excellent proliposome powder 
flowability as confirmed by angle of repose, compressibility index and Hausner ratio studies. High 
entrapment efficiency was elicited by the sorbitol-based proliposome tablets with the 1:15 w/w lipid to 
carrier ratio. Sorbitol-based proliposome tablets also had surface characteristics that made them able 
to readily accommodate the lipid phase. Furthermore, the lower friability, shorter disintegration time 
and higher drug entrapment efficiency offered by sorbitol-based proliposomes made them more 
promising than their D-mannitol formulation counterparts. Overall, it was concluded that sorbitol-
based proliposome tablets manufactured via 1:15 lipid to carrier ratio complied with all quality control 
tests employed in this study. Stability testing at three different temperatures over a prolonged period 
of 18 months resulted in marginal increases in VMD and zeta potential; contrastingly, entrapment 
efficiency of BDP was dramatically decreased at the latter months, a change more evident in HT 
stored tablets. FT conditions were found to enhance stability with extended storage time and storage 
condition exhibiting no significant effect upon the standards offered by BP. Importantly, these 
"proliposome tablets" were the only formulation that were allowed manufacture using the automated 
function (20 ± 4 tablets per min with compression force of 3.00 - 4.50 kN) of the Minipress machine; 
thus providing scope for large scale industrial manufacture of proliposome tablets, which can be 
hydrated before use. This study will take further dimensions in the future to explore the drug delivery 
applications using proliposome tablets. 
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Figure 1: SEM images of sorbitol-based proliposome tablets in (a) 1:10, (b) 1:15, and D-
mannitol-based proliposome tablets in a (c) 1:10 and, (d) 1:15 w/w lipid to carrier ratio. These 
images are typical of three such different experiments 
  
  
 
 
 
 
Figure 2: (a) Disintegration time and, (b) percentage weight loss in friability experiments for 
sorbitol and D-mannitol-based proliposome tablets at 1:10 and 1:15 w/w lipid to carrier ratios; 
with or without incorporation of BDP. Data are mean ± SD, n=3; p<0.05 
 
  
  
 
 
 
 
Figure 3: BDP concentration analysed for the entrapped, unentrapped and drug spot 
containing free BDP crystals; via HPLC for both sorbitol and D-mannitol-based proliposome 
tablets in lipid to carrier ratios of 1:10 and 1:15 w/w. Data are mean ± SD, n=3; p<0.05 
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Figure 4: Images of sorbitol-based proliposome in 1:15 w/w ratio, when (a) freshly 
manufactured as a control sample, followed by keeping them for stability purposes and 
images were taken after 18 month stability, where these tablets were kept at three different 
temperature condition i.e. (b) FT, (c) RT and, (d) HT. These images are typical of three such 
different experiments 
 
  
  
 
 
 
 
Figure 5: Post hydration of liposome suspension generated from sorbitol-based proliposome 
in 1:15 w/w ratio was analysed for (a) volume median diameter, (b) SPAN, (c) zeta potential and, 
(d) entrapment efficiency of BDP was analysed for stability purposes using different 
temperature conditions of FT, RT and HT for a period of 18 months. Data are mean ± SD, n=3; 
p<0.05 
 
  
  
 
 
Table 1: Carr’s scale of flowability representing flow properties evaluated via compressibility 
index (%) and Hausner ratio, and corresponding angle of repose (Carr, 1965) 
Compressibility index 
(%) 
Flow character Hausner ratio Angle of repose 
(degree) 
1 - 10 Excellent 1.00 - 1.11 25 - 30 
11 - 15 Good 1.12 - 1.18 31 - 35 
16 - 20 Fair 1.19 - 1.25 36 - 40 
21 - 25 Passable 1.26 - 1.34 41 - 45 
26 - 31 Poor 1.35 - 1.45 46 - 55 
32 - 37 Very poor 1.46 - 1.59 56 - 65 
˃ 38 Very, very poor ˃ 1.60 ˃ 66 
 
 
  
  
 
 
Table 2: Compressibility index (%) and Hausner ratio via tapped density, and Angle of repose 
of coarse carbohydrate carriers and proliposome powders utilising 1:10 and 1:15 w/w lipid to 
carrier ratios; for sorbitol and D-mannitol carbohydrate carriers. Data are mean ± SD, n=3  
Formulations 
Coarse 
powder 
1:10 
(with BDP) 
1:10 
(without BDP) 
1:15 
(with BDP) 
1:15 
(without BDP) 
Compressibility 
Index (%) 
     
Sorbitol 17.06 ± 0.14 14.13 ± 2.75 11.99 ± 3.65 17.81 ± 4.46 20.39 ± 1.84 
D-mannitol 34.78 ± 2.03 17.57 ± 1.96 17.05 ± 0.17 18.85 ± 1.55 18.86 ± 1.89 
 
Hausner 
Ratio 
     
Sorbitol 1.21 ± 0.01 1.17 ± 0.04 1.14 ± 0.05 1.22 ± 0.05 1.26 ± 0.03 
D-mannitol 1.53 ± 0.05 1.21 ± 0.03 1.21 ± 0.01 1.23 ± 0.02 1.23 ± 0.01 
 
Angle  
of Repose 
     
Sorbitol 28.33 ± 0.38 26.61 ± 0.08 26.08 ± 0.84 25.62 ± 1.08 25.86 ± 0.70 
D-mannitol 43.78 ± 1.30 40.88 ± 0.56 41.14 ± 1.38 40.02 ± 0.51 40.56 ± 0.89 
 
 
  
  
 
 
Table 3: Stewart assay establishing the amount of lipid phase coated on carbohydrate carriers, 
including: sorbitol or D-mannitol, with formulations ratios of 1:10 and 1:15 w/w lipid to carrier 
ratio. Data are mean ± SD, n=3 
Carrier-based proliposome 
formulations 
Lipid content (%) 
 (1:10 w/w)  (1:15 w/w) 
Sorbitol 1.98 ± 0.12 1.39 ± 0.07 
D-mannitol 2.18 ± 0.62 1.64 ± 0.28 
 
 
  
  
 
 
Table 4: Uniformity of weight (mean weight in mg) and hardness tests (i.e. crushing strength in 
Newton) for sorbitol and D-mannitol-based proliposome tablets in 1:10 and 1:15 w/w lipid to 
carrier ratios (with and without BDP). Data are mean ± SD, n=3 
 
Parameters 
 
Carrier 
1:10 
(with BDP) 
1:10 
(without BDP) 
1:15 
(with BDP) 
1:15 
(without BDP) 
Uniformity of 
weight (mg)  
 
Crushing 
strength (N) 
Sorbitol 
D-mannitol 
 
Sorbitol 
D-mannitol 
91.12 ± 2.66 
91.44 ± 4.21 
 
105.42 ± 9.67 
- 
91.97 ± 2.81 
91.58 ± 4.64 
 
110.76 ± 9.87 
- 
90.17 ± 4.30 
91.95 ± 3.95 
 
120.67 ± 12.04 
- 
91.15 ± 3.89 
92.16 ± 3.60 
 
118.56 ± 11.85 
- 
 
 
  
  
 
 
Table 5: Sorbitol-based proliposome tablets in 1:15 w/w ratio were tested in accordance to 
British pharmacopeia for uniformity of weight, disintegration test, crushing strength and 
friability test over a stability period of 18 months (i.e. 1, 2, 3, 4, 5, 6, 12 and 18 months) with 
keeping a tablets in three different temperature conditions i.e. fridge temperature (FT; 6°C), 
room temperature (RT; 22°C) and high temperature (HT; 40°C). Data are mean ± SD, n=3 
Formulations and 
months 
Weight 
variation test 
(mg) 
Disintegration 
test 
(min) 
Crushing 
strength 
(N) 
Friability 
test 
(%) 
Control 
 
FT 
1 
90.17 ± 4.13 
 
 
91.83 ± 5.53 
5.85 ± 0.66 
 
 
6.49 ± 0.57 
120.67 ± 12.04 
 
 
119.47 ± 9.47 
0.20 ± 0.03 
 
 
0.25 ± 0.06 
2 91.06 ± 4.97 6.76 ± 0.64 131.73 ± 8.71 0.21 ± 0.05 
3 92.09 ± 3.46 6.35 ± 0.06 129.60 ± 9.56 0.20 ± 0.02 
4 92.90 ± 3.54 6.89 ± 0.36 132.07 ± 8.58 0.19 ± 0.05 
5 
6 
12 
18 
92.06 ± 3.89 
91.79 ± 3.40 
91.85 ± 3.95 
91.74 ± 4.29 
6.99 ± 0.80 
7.45 ± 0.16 
6.66 ± 0.69 
6.05 ± 0.74 
122.30 ± 10.97 
122.40 ± 12.02 
121.52 ± 9.45 
124.43 ± 8.26 
0.17 ± 0.04 
0.26 ± 0.04 
0.24 ± 0.03 
0.18 ± 0.02 
RT 
1 
 
92.49 ± 4.62 
 
6.46 ± 0.13 
 
127.03 ± 11.06 
 
0.24 ± 0.04 
2 92.53 ± 3.83 7.02 ± 0.49 130.93 ± 9.48 0.19 ± 0.08 
3 91.69 ± 3.88 6.12 ± 0.56 128.43 ± 8.75 0.20 ± 0.04 
4 92.16 ± 3.22 6.53 ± 0.04 130.80 ± 10.66 0.24 ± 0.04 
5 
6 
12 
18 
92.54 ± 3.27 
91.75 ± 3.46 
92.54 ± 3.85 
92.03 ± 4.01 
4.79 ± 0.50 
5.09 ± 0.07 
4.97 ± 0.35 
3.92 ± 0.32 
128.23 ± 11.36 
126.10 ± 9.76 
128.42 ± 8.63 
129.75 ± 9.81 
0.19 ± 0.05 
0.23 ± 0.02 
0.18 ± 0.04 
0.19 ± 0.02 
HT 
1 
 
90.76 ± 5.47 
 
5.89 ± 0.29 
 
133.97 ± 11.32 
 
0.20 ± 0.07 
2 92.15 ± 4.18 5.41 ± 0.09 127.77 ± 14.09 0.23 ± 0.05 
3 91.05 ± 3.21 5.31 ± 0.05 128.83 ± 11.68 0.18 ± 0.04 
4 92.45 ± 3.12 5.23 ± 0.22 131.27 ± 10.84 0.22 ± 0.03 
5 91.09 ± 3.49 4.71 ± 0.68 136.72 ± 11.94 0.21 ± 0.07 
6 
12 
18 
92.91 ± 3.38 
92.24 ± 3.41 
91.54 ± 4.26 
3.79 ± 0.55 
3.46 ± 0.63 
3.06 ± 0.71 
130.27 ± 10.57 
129.58 ± 9.87 
132.72 ± 10.75 
0.24 ± 0.07 
0.20 ± 0.06 
0.18 ± 0.04 
 
 
 
 
